Introduction
Fasiglifam (TAK-875, Fig. 1 ) is an orally available, potent, and selective partial agonist of G protein-coupled receptor 40 (GPR40) that was developed for the treatment of type 2 diabetes mellitus (Negoro et al., 2010) . TAK-875 markedly improves glycemic control via its glucose-dependent mechanism of action, which made it a promising candidate for the treatment of type 2 diabetes mellitus, together with its low risk of hypoglycemia compared with classic insulin secretagogues. However, the clinical development of TAK-875 was unexpectedly terminated at phase III clinical trials owing to concerns about its liver safety (Takeda, 2013) . The mechanism by which TAK-875 caused liver injury still remains unclear.
After a single oral administration of 50 mg of TAK-875 to healthy subjects, was rapidly absorbed with a median time to the maximum concentration (i.e. t max ) ranged from 3 to 4 hours . The maximum plasma drug concentration (i.e. C max ) and the area under the plasma concentration-time curve from zero to infinity (i.e. AUC 0-∞ ) were 2.3 μ g/mL and 44.2 μ g·h/mL, respectively . The mean percent unbound TAK-875 values in plasma were 0.17% in subjects with normal renal function (Mayer et al., 2014) . The elimination of TAK-875 from the systemic circulation was relatively slow with a mean terminal elimination half-life (t 1/2 ) of approximately 28.1-36.6 hours .
Furthermore, TAK-875 exhibited a longer t 1/2 (31-51 h) in diabetic patients than in healthy subjects, increasing accumulation by 2.4-3.6 times in diabetic patients .
After 14 days of once-daily dosing of 50 mg TAK-875 in subjects with type 2 diabetes, the mean steady-state plasma concentration was 5.3 μ g/mL (about 10.1 μ M) .
The negligible urinary excretion values for TAK-875 (≤ 0.3%) suggested that nonrenal clearance, including hepatic metabolism, was the predominant route of elimination . Our preliminary studies indicated that after an intravenously administration of 100 mg/kg of TAK-875 to rats, TAK-875 exhibited high concentrations even at 24 h postdose This article has not been copyedited and formatted. The final version may differ from this version. Table 1 ) and the parent drug was the major related compound in circulation (Supplemental Figure 2) . The tissue disposition of TAK-875 in rats showed that its concentration was about 3 times greater in the liver than in plasma. If this liver/plasma ratio observed in rat was representative of humans, the concentration of TAK-875 in liver was expected to be about 30 μ M after multiple doses of 50 mg TAK-875 to subjects with type 2 diabetes.
Our preliminary study also showed that the serum total bile acids (TBAs) and total bilirubin (conjugated and unconjugated, TBIL) level was increased in rats following an intravenous dose of 100 mg/kg of TAK-875. It was reported that increased serum total bile acid and conjugated bilirubin concentrations are indicators of cholestasis, which accounts for approximately 30% of all cases of drug-induced liver injury (Zamek-Gliszczynski et al., 2012) . Bile acids are predominantly taken up from the sinusoidal blood into hepatocytes by the uptake transporter Na + /taurocholate co-transporting polypeptide (NTCP in humans/Ntcp in rodents) in a Na + -dependent manner (Meier et al., 1997; Trauner and Boyer, 2003; Dawson et al., 2009) . Organic anion transporting proteins (OATPs in humans/Oatps in rodents) are also involved in the hepatic uptake of bile aicds in a Na + -independent manner (Jacquemin et al., 1994; Satlin et al., 1997; Cui et al., 2001; Alrefai and Gill, 2007) . After binding to intracellular binding proteins, bile acids are primarily secreted into the canaliculus via the bile salt export pump (BSEP in humans/Bsep in rodents) and multidrug resistance-associated protein (MRP in humans/Mrp in rodents) 2 on the canalicular membrane (Kock and Brouwer, 2012) . Bilirubin, the degradation product of heme from red blood cells, is taken up into hepatocytes by members of the OATP/Oatp family, followed by conjugation with glucuronic acid to bilirubin-glucuronide and bilirubin-diglucuronide (Cui et al., 2001 ). These conjugated bilirubin glucuronides are mainly excreted into bile by MRP2/Mrp2 (Chang et al., 2013 The increase in serum TBA and TBIL concentrations may be associated with the inhibition of basolateral uptake transporters or canalicular efflux transporters. Because TAK-875 accumulates over a long time and reaches high concentrations in the liver, it may interfere with the transport of bile acids and bilirubin. Therefore, the aims of the present study were to investigate the effects of TAK-875 on the hepatobiliary disposition of bile acids and bilirubin in sandwich-cultured rat hepatocytes (SCRH) and recombinant cell lines overexpressing OATP and MRP2, and to explore the potential mechanisms for drug-induced liver injury.
This article has not been copyedited and formatted. The final version may differ from this version. Co., Tokyo, Japan). The concentrations of 11 BAs in rat serum at predose and 1 h postdose were determined using the LC-MS/MS method.
Isolation and Culture of Rat Primary Hepatocytes. Hepatocytes from male
Sprague-Dawley rats were isolated by the two-step collagenase digestion method as previously described (Annaert et al., 2001) . The viability of the obtained hepatocytes was determined using trypan blue exclusion method and was routinely > 90%. Rat hepatocytes were seeded onto collagen I-coated 24-well plates at a density of 3.0 × 10 5 cells/well and cultured in Williams' E medium supplemented with 0.1 μ M dexamethasone, 5% FBS, 100 U penicillin, 100 μg/mL streptomycin, 2 mM glutamine, and 1% ITS + . After incubation for 4 h at 37 °C under 5% CO 2 and 95% humidity, the medium was replaced with serum-free medium. After incubation for 24 h, the hepatocytes were overlaid with 0.25 mg/mL of ice-cold Matrigel to form sandwich configuration and culture medium was thereafter replaced Protein concentrations were determined using a BCA protein assay kit. HBSS containing the substrate vinblastine (Evers et al., 1998; Evers et al., 2000) was added
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The accumulation (standard and Ca 2+ -free buffer), BEI, and CL biliary for d 8 -TCA were expressed as the percentage of the control value (no inhibitor).
This article has not been copyedited and formatted. The final version may differ from this version. The permeability coefficients of vinblastine (P app,A to B and P app,B to A ) and the efflux ratio (ER) were calculated according to equations 3 and 4.
ER = P app, B to A /P app, A to B
where C T = the concentration of vinblastine on the receiver side, V = the loading volume on the receiver side, area = the surface area of the cell monolayer (0.33 cm 2 in a 24-well plate), C 0 = the initial concentration of vinblastine on the donor side, and t = incubation time. P app,A to B and P app,B to A represent the extent of permeation generated by the transport from the apical to basolateral sides and from the basolateral to apical sides, respectively.
All statistical analyses were performed using SPSS software (version 16.0 for Windows, SPSS Inc., Chicago, IL). Student's two-tailed unpaired t test was used for between-group comparisons. A P value of < 0.05 was considered statistically significant.
Results
In Vivo Cholestatic Effects of TAK-875 in Rats. We first investigated the direct interactions between TAK-875 and the serum ALT, ALP, AST, TBAs, and TBIL levels in rats to evaluate the potential cholestatic effects of TAK-875. As shown in Fig. 2 , compared with the control group, the serum levels of ALT, ALP, and AST at 24 h postdose were not significantly elevated at both doses. At the dose of 20 mg/kg of TAK-875, the serum TBAs levels and TBIL levels were comparable to the control within 8 h postdose. However, the TBA levels were significantly increased 3 to 4 times within 0.25 h to 4 h after an intravenous administration of 100 mg/kg of TAK-875, and were almost back to baseline after approximately 8 h postdose. The TBIL levels were increased 1.5 to 2.6 times within 0.25 h to 8 h following intravenous administration of 100 mg/kg TAK-875. The increase in the serum TBAs and TBIL was a fast response to administration of TAK-875.
The BAs, including TCA, CA, DCA, LCA, CDCA, UDCA, GCA, GCDCA, GDCA, GUDCA, and TCDCA, in rat serum were determined using LC-MS/MS (Table 1 ). The levels of TCA, CA, UDCA, and TCDCA in TAK-875 group were significantly increased (more than 2-fold) at 1 h postdose compared to the predose level.
Effects of TAK-875 on the Hepatobiliary Disposition of d 8 -TCA in SCRH.
The effects of TAK-875 on the accumulation of d 8 -TCA were evaluated in SCRH (Fig. 3A) . CyA, and bosentan in rat serum (Funk et al., 2001b; Kostrubsky et al., 2003) , which could cause cholestatic hepatitis in clinical settings. Considering the high accumulation of TAK-875 in liver, we speculate that TAK-875 may disturb bile acids transport, increasing the risk of hepatotoxicity. We further determined 11 BAs in rat serum at 1 h postdose after a single intravenous dose of 100 mg/kg of TAK-875 using LC-MS/MS. The levels of CA, UDCA, TCDCA, and TCA were increased > 2 times than those at predose. (Fattinger et al., 2001; Smith, 2003) . Although hepatotoxicity signals were not observed during the preclinical testing of troglitazone (Yang et al., 2014) , in vitro and in vivo studies in rats demonstrated that troglitazone and its sulfate metabolite inhibited bile acids efflux by interfering with BSEP, and this interaction may contribute to troglitazone-induced hepatotoxicity in humans (Funk et al., 2001a; Funk et al., 2001b) .
The decrease in the accumulation of d 8 -TCA in SCRH in standard buffer to 28.7% of that in control cells suggests that TAK-875 inhibits bile acids influx into hepatocytes. Because the accumulation of d 8 -TCA was inhibited to a greater extent than BEI, it seems that TAK-875 has a greater effect on hepatic bile acids uptake than on biliary bile acids efflux at the concentrations tested in rat hepatocytes. Bosentan and troglitazone exhibited similar effects on the hepatobiliary disposition of d 8 -TCA in SCRH, as observed for TAK-875 (Ansede et al., 2010) . However, CyA caused significant decreases in both BEI and CL biliary , suggesting that efflux processes were inhibited to a greater extent than the uptake processes. These results are and Oatp1b2 (Meier-Abt et al., 2004; Klaassen and Aleksunes, 2010) . TAK-875 inhibited the transporters OATP1B1 and OATP1B3 with comparable IC 50 values to Oatps overall.
The inhibition of NTCP could be regard as a hepatoprotective mechanism because it reduces TBAs accumulation in hepatocytes. Bosentan exhibited hepatotoxicity in clinical settings but was not hepatotoxic in rats, a phenomenon that was attributed to its more potent inhibitory effects of rat Ntcp (IC 50 0.71 μM) than human NTCP (IC 50 24 μM) (Leslie et al., 2007) . Thus, the differential inhibition of NTCP in rats/humans could explain the species differences in the susceptibility to drug-induced hepatotoxicity. Our results also suggest that TAK-875 impairs d 8 -TCA uptake, primarily by inhibiting NTCP, which may be a hepatoprotective mechanism in rats. Hence, if TAK-875 inhibits human NTCP to a lesser extent than rat Ntcp or does not inhibit human NTCP, bile acids are likely to be highly accumulated in human hepatocytes through the inhibition of BSEP, increasing the likelihood of cholestatic hepatotoxicity.
The increase of serum TBIL in rat after an intravenous administration of 100 mg/kg TAK-875 also indicated that the transport of bilirubin was disturbed. Bilirubin is another potentially cytotoxic endogenous substance associated with severe liver injury. It was reported that biliary excretion is the rate-limiting step of bilirubin elimination. At high intracellular concentrations, bilirubin can uncouple oxidative phosphorylation, reduce DNA This article has not been copyedited and formatted. The final version may differ from this version. (Hansen, 2001 ). Therefore, hyperbilirubinemia may provide an early warning of possible adverse effects such as neurotoxicity and hepatotoxicity. Bilirubin is taken up into hepatocytes via
OATPs and is then excreted into bile via MRP2 (the primary route) or into plasma via MRP3
(a compensatory route) in the form of bilirubin glucuronides (Jedlitschky et al., 1997; Cui et al., 2001; Keppler, 2014) . We found that TAK-875 is a strong inhibitor of OATP1B1 and OATP1B3, which suggests that TAK-875 may increase the serum concentration of unconjugated bilirubin. Indeed, in vitro, inhibition of OATP1B1 and/or OATP1B3 is associated with clinical unconjugated hyperbilirubinemia observed with several drugs, including atazanavir, indinavir, amprenavir, saquinavir, CyA, and rifampicin SV (Campbell et al., 2004; Annaert et al., 2010; Chiou et al., 2014) . Furthermore, drugs that interfere with MRP2, which directly regulates the biliary excretion of bilirubin glucuronides, may contribute to clinical hyperbilirubinemia (Chang et al., 2013) . When using CDF as the probe substrate of Mrp2 in the SCRH, TAK-875 significantly decreased the accumulation of CDF in bile canaliculi and increased its accumulation in hepatocytes, which indicates that TAK-875 is a potently inhibitor of Mrp2. The results of our in vitro studies using MDCK-MRP2 cells further confirmed the inhibitory effects of TAK-875 on MRP2. Therefore, by simultaneously inhibiting MRP2 and OATP1B1/3, TAK-875 may cause a marked increase in bilirubin concentrations, an event that may contribute to liver problems. In addition, impaired bile acids excretion slows bile flow, decreases biliary excretion of conjugated bilirubin, and increases bilirubin accumulation in hepatocytes (Hofmann, 1999) . It was also reported that the expression of MRP2 is downregulated in cholestatic conditions (Trauner et al., 1997) , which might further disrupt the elimination of bilirubin and aggravate hyperbilirubinemia. 
